- Home
- OMDA vs TSHA Comparison
OMDA vs TSHA Comparison
Compare OMDA & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMDA
- TSHA
- Stock Information
- Founded
- OMDA 2011
- TSHA 2019
- Country
- OMDA United States
- TSHA United States
- Employees
- OMDA N/A
- TSHA N/A
- Industry
- OMDA Medical/Nursing Services
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- OMDA Health Care
- TSHA Health Care
- Exchange
- OMDA Nasdaq
- TSHA Nasdaq
- Market Cap
- OMDA 1.3B
- TSHA 1.3B
- IPO Year
- OMDA 2025
- TSHA 2020
- Fundamental
- Price
- OMDA $22.88
- TSHA $4.57
- Analyst Decision
- OMDA Strong Buy
- TSHA Strong Buy
- Analyst Count
- OMDA 7
- TSHA 8
- Target Price
- OMDA $24.86
- TSHA $9.38
- AVG Volume (30 Days)
- OMDA 489.8K
- TSHA 11.2M
- Earning Date
- OMDA 11-17-2025
- TSHA 11-12-2025
- Dividend Yield
- OMDA N/A
- TSHA N/A
- EPS Growth
- OMDA N/A
- TSHA N/A
- EPS
- OMDA N/A
- TSHA N/A
- Revenue
- OMDA $209,827,000.00
- TSHA $8,098,000.00
- Revenue This Year
- OMDA $43.42
- TSHA N/A
- Revenue Next Year
- OMDA $20.01
- TSHA N/A
- P/E Ratio
- OMDA N/A
- TSHA N/A
- Revenue Growth
- OMDA 135.27
- TSHA N/A
- 52 Week Low
- OMDA $14.14
- TSHA $1.05
- 52 Week High
- OMDA $28.40
- TSHA $5.40
- Technical
- Relative Strength Index (RSI)
- OMDA N/A
- TSHA 69.54
- Support Level
- OMDA N/A
- TSHA $3.10
- Resistance Level
- OMDA N/A
- TSHA $5.40
- Average True Range (ATR)
- OMDA 0.00
- TSHA 0.32
- MACD
- OMDA 0.00
- TSHA 0.17
- Stochastic Oscillator
- OMDA 0.00
- TSHA 66.85
About OMDA Omada Health Inc. Common Stock
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The Company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.